Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy

Emanuel Kaltenecker¹, Julia Schleihauf¹, Christian Meierhofer¹, Nerejda Shehu¹, Naira Mkrtchyan¹, Alfred Hager¹, Andreas Kühn¹, Julie Cleuziou²³, Karin Klingel¹, Heide Seidel⁵, Martin Zenker⁶, Peter Ewert¹, Gabriele Hessling¹, Cordula M. Wolf¹

¹Department of Congenital Heart Disease and Pediatric Cardiology, ²Department of Cardiovascular Surgery, ³(INSURE) Institute for Translational Cardiac Surgery, German Heart Center Munich, Technical University of Munich, Munich, Germany; ⁴Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany; ⁵Institute of Human Genetics, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany; ⁶Institute of Human Genetics, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany

Contributions: (I) Conception and design: CM Wolf, E Kaltenecker; (II) Administrative support: CM Wolf, P Ewert, G Hessling; (III) Provision of study materials or patients: K Klingel, A Hager, A Kühn, J Cleziou, H Seidel, M Zenker; (IV) Collection and assembly of data: E Kaltenecker, J Schleihauf; (V) Data analysis and interpretation: CM Wolf, E Kaltenecker, J Schleihauf, C Meierhofer, N Shehu, N Mkrtchyan, K Klingel; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Cordula M. Wolf. Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, Lazaretstrasse 36, 80636 Munich, Germany. Email: wolf@dhm.mhn.de.

Background: To compare outcome and cardiac pathology between patients with Noonan syndrome (N-HCM) and sarcomere protein-associated (S-HCM) childhood onset hypertrophic cardiomyopathy (HCM).

Methods: Clinical data were recorded from medical charts. Primary endpoint was survival. Secondary endpoints were survival without hospitalization, without intervention or without arrhythmic events. Functional clinical status and results from genetic testing, imaging, electrocardiographic (ECG) studies, cardiopulmonary exercise testing (CPET) and histopathology were compared between groups.

Results: Childhood HCM was diagnosed in 29 N-HCM and 34 S-HCM patients. Follow-up time was greater than 10 years in more than half of all patients. Mortality was below 7% and not different between groups. Children with N-HCM presented at a younger age and there was less time of survival without hospitalization for heart failure or intervention in N-HCM compared to S-HCM patients. Clinical functional status improved over time in N-HCM patients. On long-term follow-up, left ventricular posterior wall thickness indexed to body surface area decreased in N-HCM and increased in S-HCM patients. There was a trend to lower risk for severe arrhythmic events in N-HCM patients and only S-HCM individuals received an implantable cardioverter-defibrillator. There were no differences between groups in ventricular function, ECG and CPET parameters. Myocardial fibrosis as assessed by histopathology of myocardial specimens and cardiovascular magnetic resonance with late gadolinium enhancement or T1 mapping was present in both groups.

Conclusions: When compared to S-HCM patients, children with N-HCM have increased morbidity during early disease course, but favorable long-term outcome with low mortality, stagnation of myocardial hypertrophy, and low risk for malignant arrhythmias.

Keywords: Hypertrophic cardiomyopathy (HCM); childhood; Noonan syndrome; outcome; disease course

Submitted Mar 11, 2019. Accepted for publication May 16, 2019.
doi: 10.21037/cdt.2019.05.01
View this article at: http://dx.doi.org/10.21037/cdt.2019.05.01
Introduction

Whereas adult hypertrophic cardiomyopathy (HCM) is mainly caused by mutations in genes encoding for components of the sarcomere, neonatal and childhood onset HCM is often associated with Noonan syndrome. Within the past decade, extensive clinical and experimental research has contributed to our understanding of sarcomere-associated HCM (S-HCM). European (1,2) and North-American (1,3) guidelines facilitate the management of patients with S-HCM, however those exclude patients with syndromic HCM and far less is known about outcome, clinical course and cardiac pathology of patients with Noonan syndrome-associated hypertrophic cardiomyopathy (N-HCM). A detailed understanding of disease course is necessary to provide optimal counseling, risk stratification and treatment.

Noonan syndrome has a prevalence of 1:1,000–1:2,500 (4,5) and belongs to the spectrum of diseases called “RASopathies” (alternatively called neuro-cardio-facial-cutaneous syndromes). It is caused by autosomal-dominant mutations in genes of the mitogen-activated protein kinase (MAPK) signaling pathway (5). Patients present with characteristic patterns of facial anomalies, short stature, congenital heart defects, hematologic disorders, and mental retardation (6).

HCM occurs in about 15% (7) to 20% (8,9) of patients with Noonan-syndrome. Mutations in the \textit{PTPN11}, \textit{RAF1} and \textit{RIT1} genes are most often associated with the occurrence of HCM in Noonan-patients (9-12). Patients present clinically with myocardial hypertrophy (13), right and/or left ventricular outflow tract (LVOT) obstruction, diastolic and/or systolic dysfunction (7), and rarely with arrhythmia (8,9). Similar to S-HCM (14), fibrotic myocardial changes (13,15) and myocyte disarray (13,16) have been described in N-HCM. Therapeutic options are limited to medical treatment of heart failure symptoms, or surgical septal myectomy to relieve drug-refractory severe left and/or right ventricular outflow tract obstruction (17,18). New therapies directly targeting the RAS/MAPK pathways are currently under investigation (19-21).

This single center cohort study compares long-term outcome and cardiac pathology between patients with genetically diagnosed childhood onset N-HCM and S-HCM.

Methods

Study design

All patients with childhood HCM presenting at the German Heart Center Munich, a tertiary care university hospital, between January 1978 and July 2018 were included in the study.

Demographic, clinical, molecular genetic testing result, transthoracic echocardiographic (TTE), electrocardiographic (ECG), 24-hour ambulatory Holter ECG, cardiopulmonary exercise testing (CPET), cardiovascular magnetic resonance (CMR), surgical, histopathologic and other patient-related data were collected retrospectively by review of patients’ charts within 1, 5 and 10 years after diagnosis, and at last follow-up.

Molecular genetic DNA-based analysis was carried out as recommended by European and North-American guidelines (2,22-24) in accredited laboratories only and criteria for assessing variant pathogenicity were based on the variant type, variant database, literature review, frequency in the general population, and \textit{in silico} analysis according to the ACMG (American College of Medical Genetics and Genomics) guidelines (25,26).

Patients were classified into two groups for comparison: patients with a genetic or clinical diagnosis of Noonan syndrome and HCM (N-HCM) (4) and patients with a genetic diagnosis of sarcomere protein-associated HCM (S-HCM) (2,27).

Primary endpoint was death. Secondary endpoints were survival until hospitalization for heart failure, survival until hospitalization for intervention, and survival until first severe arrhythmic event. Intervention was defined as either percutaneous cardiac intervention or cardiac operation. Severe arrhythmic event was defined as sudden cardiac death, aborted sudden cardiac death, appropriate ICD discharge or sustained ventricular or supraventricular tachycardia.

Inclusion and exclusion criteria

All children with a primary diagnosis of HCM between birth and the age of 18 years and a positive genetic result for HCM or Noonan syndrome, or a clinical diagnosis of Noonan syndrome were included in the study (also see online supplement methods for further details). Patients
with other complex structural heart disease and with other genetic, metabolic or neuromuscular disorders were excluded.

**Clinical data, imaging and histopathology**

Data were collected as previously described (28). Please see online supplement methods for detailed description of imaging, ECG, CPET, and histopathology.

**Statistics**

Statistical analysis was performed with the SPSS software version 22.0.0 (SPSS Inc., IBM Company, Chicago, Illinois, USA). The time-related probability of survival until primary endpoint and secondary endpoints were estimated with the Kaplan-Meier method and compared by the log-rank test between groups. Data were censored at the time of event or the latest time of follow-up. Continuous variables are expressed as means (95% confidence interval) or median (range: minimum–maximum), according to sample distribution. Differences between N-HCM and S-HCM patients were analyzed by independent t-test for normally distributed or Mann-Whitney Wilcoxon test for not normally distributed data. Longitudinal data were compared with paired t-test or Wilcoxon signed rank tests where appropriate. Categorical variables are given as percentages of group totals and were analyzed by Pearson Chi Square or Fisher exact test. A P value of <0.05 (two-sided) was considered statistically significant.

**Ethics**

This study was approved by the Technical University of Munich Institutional Review Board (ethical approval number 243/17S, 10/16/2017).

**Results**

**Patients characteristics**

Medical records were screened for of all patients diagnosed with childhood onset HCM and 75 patients were identified. Of those, a genetic or clinical diagnosis of Noonan syndrome (N=24) or Noonan syndrome with multiple lentigines (N=5) was made in 29 patients and a genetic diagnosis of sarcomere-protein associated HCM in 34 patients (Figure 1). Twelve patients were excluded from further analysis due to lacking clear clinical characterization or genetic information. On last follow-up, TTE and ECG were performed in all patients, genetic testing, 24-hour Holter ECG, CPET, CMR, and histopathology in a subset of patients. A pathogenic mutation was identified in 55 out of 63 patients tested (87.3%). Pathogenic variants in the genes *PTPN11* (about half of patients presenting with Noonan syndrome and multiple lentigines, NS-ML, or previously called LEOPARD syndrome) and *RAF1* were the most prominent mutations detected in N-HCM. S-HCM patients were most commonly affected with mutations in *MYH7* and *MYBPC3*. Four S-HCM patients carried more than one mutation (Figure 1).

Gender distribution was similar between N-HCM and S-HCM patients. Most N-HCM patients were diagnosed within their first year of life at a younger age as compared to S-HCM patients, who were mostly first diagnosed within early school years. Clinical follow-up time after diagnosis was similar between groups and was more than 10 years in half of all patients.

Family history was negative in most N-HCM patients and there was no family history of sudden cardiac death in this group.

N-HCM patients were more likely to carry a concomitant cardiac diagnosis, which included right ventricular outflow tract obstruction, mitral valve abnormalities and pulmonic...
valve pathology.

No S-HCM but most N-HCM patients presented with additional clinical features, such as facial dysmorphologies, short stature, or skin lesions (Table 1).

**Clinical outcome**

Primary study endpoint was death. There were two deaths in the N-HCM (6.9%) and no death in the S-HCM group (Figure 2A). One NS-ML patient carrying a PTPN11 mutation died in the immediate postoperative period after septal myectomy from multi-organ failure at the age of 4.3 months. The second patient carried a clinical diagnosis of Noonan syndrome and died at 11.3 years of age due to heart failure secondary to undiagnosed supraventricular tachycardia in an outside hospital.

Survival without hospitalization for heart failure or intervention was shorter in N-HCM as compared to S-HCM patients (Figure 2B,C). N-HCM patients were more likely to require septal myectomy compared to S-HCM patients (Table 1). Concomitant procedures included valve surgery in 10 N-HCM and 1 S-HCM patient, right ventricular outflow tract resection in 2 N-HCM patients, and relief of myocardial muscle bridges in 1 S-HCM patient.

The occurrence of arrhythmias on ECG, 24-hour ECG or CPET, including supraventricular and ventricular extra beats and tachycardia, was equal between groups (Table 1). One of 29 (3.4%) N-HCM and 5 of 34 (14.7%) S-HCM patients reached the secondary endpoint severe arrhythmic event (P=0.205, Fishers exact test, and Figure 2D). Only S-HCM patients received an ICD for primary prevention in most of those patients and half of the patients with ICD experienced at least one appropriate discharge (Table 1).

**Clinical features and cardiac pathology**

Compared to S-HCM patients, N-HCM patients presented in a higher NYHA/Ross functional class at the time of diagnosis which improved over time (Figure 3A). Peak VO₂ on CPET (Table 1) and the number of cardiac medications on last follow-up were similar between groups. 56% of N-HCM and 71% of S-HCM patients used beta-blockers on last follow-up (P=0.5, Fishers exact test).

Relative thickness of the left ventricular posterior wall and interventricular septum decreased over time in N-HCM and increased in S-HCM patients (Figure 3B,C), even if separated into groups of patients without versus after surgical septal myectomy (Figure 3D).

There were no differences in systolic or diastolic ventricular function between groups, as assessed by ventricular ejection fraction, global longitudinal strain, left atrial size, mitral valve E/A ratio, or septal and lateral E/E’ on TTE, respectively (Table S1). Evidence of focal or interstitial fibrosis as assessed by histopathology or late

<table>
<thead>
<tr>
<th>Table 1 Patient characteristics and clinical findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Characteristics</strong></td>
</tr>
<tr>
<td><strong>N-HCM</strong></td>
</tr>
<tr>
<td><strong>S-HCM</strong></td>
</tr>
<tr>
<td><strong>P value</strong></td>
</tr>
<tr>
<td>Male, n (%)</td>
</tr>
<tr>
<td>17/29 (58.6)</td>
</tr>
<tr>
<td>21/34 (61.8)</td>
</tr>
<tr>
<td>0.501*</td>
</tr>
<tr>
<td>Age at diagnosis (years), median [range]</td>
</tr>
<tr>
<td>0.0 [0.0–11.0]</td>
</tr>
<tr>
<td>6.0 [0.0–18.8]</td>
</tr>
<tr>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Follow-up time (years), median [range]</td>
</tr>
<tr>
<td>10.9 [0.1–30.5]</td>
</tr>
<tr>
<td>9.9 [0.0–33.7]</td>
</tr>
<tr>
<td>0.720*</td>
</tr>
<tr>
<td>&lt;5 years, n (%)</td>
</tr>
<tr>
<td>7/29 (24.1)</td>
</tr>
<tr>
<td>10/34 (29.4)</td>
</tr>
<tr>
<td>5–10 years, n (%)</td>
</tr>
<tr>
<td>6/29 (20.7)</td>
</tr>
<tr>
<td>7/34 (20.6)</td>
</tr>
<tr>
<td>&gt;10 years, n (%)</td>
</tr>
<tr>
<td>16/29 (55.2)</td>
</tr>
<tr>
<td>17/34 (50.0)</td>
</tr>
<tr>
<td>Family history</td>
</tr>
<tr>
<td>Negative, n (%)</td>
</tr>
<tr>
<td>19/28 (67.8)</td>
</tr>
<tr>
<td>10/33 (30.3)</td>
</tr>
<tr>
<td>0.004*</td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy, n (%)</td>
</tr>
<tr>
<td>7/28 (25.0)</td>
</tr>
<tr>
<td>18/33 (54.5)</td>
</tr>
<tr>
<td>0.018*</td>
</tr>
<tr>
<td>Sudden cardiac death, n (%)</td>
</tr>
<tr>
<td>0/20 (0.0)</td>
</tr>
<tr>
<td>6/33 (18.2)</td>
</tr>
<tr>
<td>0.02*</td>
</tr>
<tr>
<td>Concomitant cardiac diagnosis</td>
</tr>
<tr>
<td>None, n (%)</td>
</tr>
<tr>
<td>7/29 (24.1)</td>
</tr>
<tr>
<td>29/34 (85.3)</td>
</tr>
<tr>
<td>&lt;0.001*</td>
</tr>
</tbody>
</table>

Table 1 (continued)
Table 1 (continued)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N-HCM</th>
<th>S-HCM</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial bridging of coronary artery, n (%)</td>
<td>0/29 (0.0)</td>
<td>1/34 (2.9)</td>
<td>1.0*</td>
</tr>
<tr>
<td>Mitral valve pathology, n (%)</td>
<td>10/29 (34.5)</td>
<td>3/34 (8.8)</td>
<td>0.026*</td>
</tr>
<tr>
<td>Pulmonic valve pathology, n (%)</td>
<td>7/29 (24.1)</td>
<td>0/34 (0.0)</td>
<td>0.003*</td>
</tr>
<tr>
<td>Aortic valve pathology, n (%)</td>
<td>0/29 (0.0)</td>
<td>1/34 (2.9)</td>
<td>1.0*</td>
</tr>
<tr>
<td>Right ventricular outflow tract obstruction, n (%)</td>
<td>11/29 (37.9)</td>
<td>0/34 (0.0)</td>
<td>&lt;0.001*</td>
</tr>
</tbody>
</table>

Clinical features

- None, n (%) | 2/29 (9.5) | 34/34 (100.0) | <0.001* |
- Facial dysmorphologies, n (%) | 23/29 (79.3) | 0/34 (0.0) | <0.001* |
- Short stature, n (%) | 24/29 (82.8) | 0/34 (0.0) | <0.001* |
- Multiple lentigines, n (%) | 5/29 (17.2) | 0/34 (0.0) | 0.019* |

Septal myectomy

| n (%) | 18/29 (62.1) | 7/34 (20.6) | 0.002* |
| Age (years), median [range] | 1.4 [0.2–15.0] | 10.5 [1.0–17.3] | 0.060* |

Implantable cardioverter-defibrillator, n (%) | 0/21 (0.0) | 9/34 (26.5) | 0.003* |

Primary prevention

| Age (years), median [range] | NA | 14.8 [4.3–40.5] | NA |

Secondary prevention

| Age (years), median [range] | NA | 2/9 (22.2) | NA |

Appropriate discharge, n (%) | NA | 5/9 (55.6) | NA |

Arrhythmia

- None, n (%) | 14/29 (48.3) | 14/34 (41.2) | 0.618* |
- Mild, n (%) | 12/29 (41.4) | 14/34 (41.2) | 1.0* |
- Severe, n (%) | 3/29 (10.3) | 6/34 (17.6) | 0.488* |

Cardiovascular magnetic resonance tomography

| Age (years), median [range] | 14.9 [6.5–30.7] | 14.1 [1.1–40.1] | 0.558* |
| Myocardial mass (g/m²), median [range] | 105 [55–339] | 95 [39–213] | 0.885* |
| Apical aneurysm, n (%) | 3/11 (27.3) | 1/20 (5.0) | 0.115* |
| Late gadolinium enhancement positive, n (%) | 4/11 (36.4) | 11/21 (52.4) | 0.472* |
| T1 extracellular volume fraction, mean (95% CI) | 29 [26–33] | 28 [26–30] | 0.136* |

Histopathology

| Fibrosis (%), mean (95% CI) | 11 [5–16] | 6 [4–9] | 0.073* |
| Mild myocyte disarray, n (%) | 3/7 (42.9) | 3/4 (75.0) | 0.545* |
| Severe myocyte disarray, n (%) | 4/7 (57.1) | 1/4 (25.0) | 0.545* |

Cardiopulmonary exercise testing

| VO₂ max (% norm), mean (95% CI) | 72 [60–86] | 77 [70–84] | 0.589* |

---

* Chi-squared-test; †, Mann Whitney Wilcoxon test; ‡, independent t-test N-HCM vs. S-HCM; ‡, classification of arrhythmia: on ECG, Holter or CPET: none, mild: premature ventricular or supraventricular beats, severe: non-sustained and sustained ventricular or supraventricular tachycardia and appropriate discharge implantable cardioverter-defibrillator; N-HCM, patients with Noonan syndrome and hypertrophic cardiomyopathy; S-HCM, patients with sarcomere protein-associated hypertrophic cardiomyopathy; N/n, number; NA, not available.
gadolinium enhancement (LGE) and T1 map on CMR, respectively, was found in both groups (Table 1). Apical aneurysm was detected on CMR in 3 N-HCM and 1 S-HCM patient (Table 1).

On sub analysis, there were no differences in patient characteristics, clinical features and cardiac pathology between N-HCM patients carrying distinct mutations (data not shown).

Discussion

General outcome and natural history of Noonan patients has been described before (7-9,18,29-32), but most of those data lack genetic information and detailed clinical description, such as time course of disease development, clinical functional status, imaging, electrophysiologic information, and a direct comparison to patients with childhood onset sarcomere-protein related HCM.
Cardiovasc Diagn Ther 2019 | http://dx.doi.org/10.21037/cdt.2019.05.01

This is the first study to directly compare outcome and detailed cardiac features between patients with childhood onset HCM carrying a genetic diagnosis of Noonan syndrome and patients with sarcomere protein-associated HCM in a large single center cohort.

The main findings of the present study are a low mortality and a favorable long-term outcome of N-HCM patients despite presentation during infancy and despite significant morbidity during the first years of life. The current data also provide evidence that although there are similar features on CMR imaging and histopathology between N-HCM and S-HCM patients, there is, in contrast to S-HCM patients, no progression but rather regression of myocardial hypertrophy. There was a trend to a lower occurrence of severe arrhythmic events in N-HCM as compared to S-HCM patients.

The low mortality of below 7% described in this study differs from most previous study reports (8,32-35), which state higher mortality rates specifically in patients diagnosed during early infancy and presenting with severe heart failure. The main reason for the discrepancy of findings is that data from the current study derive from a tertiary care referral center. Very sick infants who deceased prior at an outside hospital or children with infant HCM of other
etiolgies are not reflected in the present statistics. Second, aggressive medical and interventional treatments during early disease course as depicted by the secondary endpoint Kaplan-Meier-curves in the current study might have contributed to low mortality in N-HCM patients.

Compared to S-HCM patients, N-HCM patients present with worse clinical status and at an earlier age, requiring hospital admissions and interventions early in life. The reason for intervention included relief of LVOT obstruction in most of N-HCM patients, and valve operation and/or relief of right ventricular outflow tract obstruction in a subset of those patients. In comparison, cardiac procedures other than relief of LVOT obstruction were rare in S-HCM patients.

Clinical functional status improved in N-HCM patients over time and in contrast to S-HCM patients there is no progression of left ventricular hypertrophy standardized to body surface area (z-scores) assessed by TTE over time beyond childhood in most of N-HCM patients. Instead, both left ventricular posterior wall and interventricular septal z-scores decreased over time in N-HCM patients. Because surgical septal myectomy was performed in most of those patients, comparison of myocardial z-scores between diagnosis and last follow-up was also done separately for patients requiring surgical septal myectomy and those who did not. This sub-analysis again showed that myocardial z-scores regressed in both groups, but due to small patient numbers this did not reach statistical significance in patients not undergoing septal myectomy. Spontaneous regression of HCM was also reported by others (9), but detailed TTE findings were not presented in that study. In contrast, non-syndromic familial HCM due to sarcomere protein-associated mutations tend to worsen over time (36). Distinct underlying molecular pathology might account for this clinical observation. Altered biophysical properties and activation of pro-hypertrophic and -fibrotic transcription factors are known to cause HCM in patients with sarcomere protein-associated mutations (37,38). Alteration in the RAS/MAPK signaling pathway cause hypertrophy by a distinct mechanism, which might be more pronounced during perinatal development and less in post-natal life (39,40).

Histopathologic results of the current study showed that there was a similar amount of quantified fibrosis on histopathology performed on myocardial specimens. Similar histopathologic changes were described in small case series (30) or single patient case reports (13,16). The fact that specimens in the current study were gained at the time of septal myectomy during early childhood in most of the N-HCM patients provides evidence that in contrast to S-HCM, in which pathologic myocardial remodeling occurs over time, fibrotic changes in N-HCM patients are already present during early disease course in severely hypertrophic areas that require surgical resection. Myocardial changes persist in N-HCM patients as CMR on follow-up shows LGE as a correlate for focal fibrosis and increased interstitial fibrosis assessed by CMR T1 mapping.

CMR also showed the presence of apical aneurysms in three N-HCM patients. With the exception of one case report (15), there are no studies on CMR findings in N-HCM patients so that the overall prevalence is unknown in this population. Apical aneurysms are associated with increased morbidity in patients with sarcomere-related HCM (41,42) but the significance in N-HCM patients has not been described yet. In the current study, none of the three N-HCM patients with apical aneurysms required specific treatment or experienced severe arrhythmic or thromboembolic events at this point.

HCM is the main reason for sudden arrhythmic death in adolescents and young adults (43,44). No N-HCM patient suffered sudden cardiac death, aborted sudden death, or required an ICD in the current study. However, severe arrhythmias, including sustained supraventricular tachycardia and non-sustained ventricular tachycardia occurred in 3 N-HCM patients. In contrast, 2 patients with S-HCM presented after cardiopulmonary resuscitation and half of S-HCM patients with an ICD had appropriate discharges. Those findings, together with the findings reported by other authors (8,9,16) suggest that N-HCM patients are at lower risk for sudden cardiac death. Ventricular tachycardia and sudden death were reported in another N-HCM population (7), but those patients had additional major cardiac anomalies which could explain their increased risk for malignant arrhythmias. Risk stratification for sudden death is of highest importance in patients with HCM (45-48), but data about risk stratification in N-HCM patients are lacking and numbers of N-HCM patients experiencing severe arrhythmic events in the current study were too small to evaluate for risk factors in this population. Therefore, risk stratification for malignant arrhythmias at this point needs to be performed on an individual base.

Taken together, clinical outcome of affected patients is directly related to distinct disease courses of N-HCM patients compared to S-HCM patients. N-HCM patients can be severely affected in the perinatal period and during infancy which requires aggressive medical or interventional/surgical management at this early stage in life. This contrasts with S-HCM patients in whom
surgical interventions are less frequently required during early childhood but in whom sudden cardiac death risk stratification and possibly implantation of an ICD becomes critical during adolescence and young adulthood.

The current study’s observations might impact clinical management of N-HCM patients. In contrast to S-HCM patients, treatment of LVOT obstruction or heart failure in N-HCM patients mostly occurs early in life during infancy. Disturbed RAS signaling causes HCM in Noonan patients (40,49) and small-molecule therapies inhibiting the appropriate pathway may have the potential to prevent or reverse cardiac pathology in affected patients. Inhibition of protein kinase B (Akt) (19) or mTOR (40,50) has shown to be effective treatment options in RASopathy mouse models and one case report describes improvement of heart failure symptoms in a critically ill infant with Noonan syndrome and multiple lentigines by treatment with the mTOR inhibitor rapamycin (21). However, those personalized therapies are still experimental and reserved for patients with critical disease.

Study limitations

The usual limitations of a single center retrospective study, such as selection bias and inter-observer variability for clinical and echocardiographic evaluations performed by different physicians, apply to this data analysis. The prevalence of childhood HCM in general and in the setting of Noonan syndrome low. The small number of subjects limits statistical power and the feasibility of subgroup analysis in the cohort of the current study. Some associations were clinically but not statistically significant and do only have descriptive character. Due to the strict inclusion criteria of a genetic diagnosis in the S-HCM group, children with familial non-syndromic HCM and a negative genetic result were not included in this analysis and data might thus be not representative for this group. CMR and CPET were not performed in all patients due to age or body size, or other contraindications. CMR findings were used in this study to assess the amount and distribution of focal and interstitial fibrosis. Despite good correlation of imaging and histopathologic changes (51), CMR might not reflect true cellular myocardial changes.

Conclusions

N-HCM patients have a favorable long-term outcome with overall low mortality despite significant morbidity requiring hospitalization and intervention early in life. In contrast to S-HCM patients there is stagnation of myocardial hypertrophy and a low risk for malignant arrhythmias over time in the N-HCM population. Findings of this study impact counseling of patients with Noonan syndrome and childhood onset HCM.

Acknowledgments

We would like to thank and dedicate this work to PD Dr. S Fratz who passed away after initiating this study. All phases of this study were supported by the Gerd-Killian Award Deutsche Herzstiftung e.V. (CM Wolf).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: This study was approved by the Technical University of Munich Institutional Review Board (ethical approval number 243/17S, 10/16/2017).

References

22. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011;8:1308-39.


Online supplement patients and methods

Inclusion and exclusion criteria

All children with a primary diagnosis of hypertrophic cardiomyopathy (HCM) between birth and the age of 18 years were included in the study. The diagnosis of HCM was based on clinical evaluation and cardiac catheterization or transthoracic echocardiography (TTE) detecting myocardial hypertrophy (defined as a z-score of greater than 2) in the absence of another cardiac or systemic disease causing the degree of left ventricular hypertrophy identified (1,2).

Since Noonan syndrome can be diagnosed by typical syndromic features, such as craniofacial abnormalities, short stature, failure to thrive, etc., all patients with a clinical or molecular genetic diagnosis of Noonan syndrome or Noonan syndrome with multiples lentigines (NS-ML) were included in the Noonan syndrome HCM cohort. In the group of sarcomere protein-associated HCM, only patients with molecular testing positive for a pathogenic or likely pathogenic variant were included, because of the lack of clear clinical features in this cohort and because HCM in genotype-negative patients could have distinct etiologies, such as mitochondrialopathy, Fabry disease, or storage disease.

Clinical data, imaging and histopathology

The total number of clinical patients’ visits varied according to patients’ compliance and the physicians’ practice. Data were collected retrospectively from regular clinical visits and data were recorded from the last possible timepoint within 1, 5, and 10 years after diagnosis, and at last follow-up. Hence, study data from up to 4 studies were recorded for analysis.

TTE was performed using standard equipment in routine clinical practice and using standard views according to the American Society of Echocardiography guidelines (3-5). Echopac Software (General Electric, Vingmed, Horten, Norway) was used for offline-analysis. Measurements of left ventricular wall thickness were standardized to body surface area (z-scores), which describe how many standard deviations lie above or below a size-matched population given a specific measurement. Given the large variability of age and size in children, z-scores are commonly used in pediatric cardiology. The left ventricular outflow tract (LVOT) gradient was assessed under resting conditions, using continuous wave Doppler echocardiography (6,7).

On 12-lead ECG, heart rate, arrhythmia, time intervals, patterns of myocardial ischemia and hypertrophy were documented (8). Occurrence of arrhythmia was assessed additionally by ambulatory Holter ECG, if existing, from the memory of a permanent pacemaker, recording activity and shock frequency.

Cardiopulmonary exercise testing (CPET) was performed in sitting position on a bike-ergometer. A standardized testing protocol was performed and physical working capacity, peak oxygen uptake (peak VO₂), evidence of myocardial ischemia or arrhythmia and escalation of heart rate or blood pressure during or after exertion were recorded (9).

CMR was performed on a 1.5 Tesla MR scanner (Magnetom Avanto, Siemens Healthcare, Software Version VD13, Erlangen, Germany). Cine images (balanced steady-state free precession) were acquired in short axis and four chamber orientations, in breath hold or in free breathing in younger children not able to hold the breath, to evaluate the ventricular volume, ventricular mass, ejection fraction and regional wall anomalies. Late Gadolinium Enhancement (LGE) was acquired using a T1-weighted phase-sensitive inversion recovery sequence 10 minutes after intravenous administration of an extracellular MR contrast agent (Gadopentetat) to detect focal fibrosis (10).

Native and post contrast T1 mapping, using a modified look-locker inversion recovery sequence (MOLLI) (11), with non-rigid motion correction reconstruction, were assessed in short axis and four chamber orientation. Image quality was assessed by revising T1 maps and error maps of the region of interest. Extracellular volume (ECV) was calculated as previously described (12).

Criteria for surgical intervention at the German Heart Center in Munich were LVOT obstruction ≥50 mm Hg at rest or with provocative maneuvers, associated with New York Heart Association (NYHA) functional classes/Ross ≥ III despite maximum medical management (13,14). The septal myectomy in the present cohort was performed as previously described (15-17).

Cardioverter-defibrillator (ICD) was implanted for secondary prevention in HCM patients who have survived a cardiac arrest caused by ventricular fibrillation or sustained ventricular tachycardia according to the European (2,18) and North-American guidelines (18,19). ICD implantation as primary prevention included individual risk assessment based on conventional risk factors, such as massive LV hypertrophy, syncope of unknown etiology, family history
of sudden death <40 years/age, non-sustained ventricular tachycardia, and abnormal blood pressure response on stress test (20-23). Additionally, the online available risk prediction model for sudden cardiac death in HCM (http://www.doc2do.com/hcm/webHCM.html) was used for patients older than 16 years of age (24).

Histopathologic examination of myectomy specimens was performed in a blinded fashion by a cardiovascular pathologist. Presence of myocyte disarray was assessed on hematoxylin/eosin stained slides. For the quantification of cardiac fibrosis, paraffin-embedded specimens were stained with Masson's trichrome, reflecting myocyte necrosis as well as interstitial fibrosis, and were analyzed by light microscopy using the interactive program Quantuepatho. Fibrotic areas were digitally dissected on 5 µm thick sections. The percentage area of fibrosis in the section was evaluated by dividing the sum of the fibrotic areas of the section by that of the total tissue area as described previously (25).

### References

4. Weidemann F, Eyskens B, Jamal F, et al. Quantification of regional left and right ventricular radial and longitudinal function in healthy children using ultrasound-based...


